This website is intended for Medical Professionals only. By using this site you confirm that you are a healthcare professional.

Recurrent miscarriage: diabetes drug could ... An existing drug can be used to improve the womb for pregnancy, ... (08 Jan 2020)
Nerve Stimulation May Benefit Women with ... A treatment involving electrical nerve stimulation helped women ... (08 Jan 2020)
Cancer drugs could potentially treat COPD, ... New research from the University of Sheffield shows a certain ... (08 Jan 2020)
Tea drinkers live longer Drinking tea at least three times a week is linked with a longer ... (08 Jan 2020)

Liraglutide effective in reducing sleep apnoea in affected obese patients, most likely through weight loss

New research presented at this year’s European Congress on Obesity (ECO) in Prague, Czech Republic, shows that the drug liraglutide, now approved for treatment of obesity as well as for type 2 diabetes in Europe and the USA, reduces occurrence of sleep apnoea more effectively than placebo, most likely through its promotion of weight loss. The study is by Dr Gary Zammit, Clinilabs, New York, NY, USA, and colleagues.
This study of data collected in the SCALE Sleep Apnoea Trial which analysed the relationship weight loss, sleep apnoea and quality of life. Obese adults (72% male, mean age 49 years, apnoea-hypopnoea index [AHI] 49.2 events/hour, mean body weight [BW] 117.6 kg) with moderate or severe obstructive sleep apnoea (OSA) and unable/unwilling to use continuous positive airway pressure therapy were treated with liraglutide 3.0 mg (n=180) or placebo (n=179), both in addition to diet and exercise counselling, for 32 weeks.
The researchers found that liraglutide 3.0 mg reduced AHI (–12.2 vs –6.1 events/hour) and BW (-5.7% vs –1.6%) vs placebo after 32 weeks. They also found that AHI reduction was significantly associated with weight loss (WL), irrespective of treatment, suggesting that the weight loss effects of liraglutide were responsible for its association with improving sleep apnoea symptoms. The reduction in AHI per %WL depended on baseline AHI, with reductions of 0.7, 1.4 and 2.8 events/hour for base¬line AHI cohorts <30, 30–59 and =60 events/hour, respectively. Greater WL was also significantly associated with greater im¬provement in various quality of life factors, including reductions in feelings of sleepiness, improved blood oxygen saturation, and improved total sleep time.
The authors conclude: “Greater weight loss and reduction of sleep apnoea episodes were more likely with liraglutide 3.0 mg than placebo. Greater im¬provements in sleep apnoea endpoints and quality of life were significantly asso¬ciated with greater weight loss, irrespective of how the weight loss was achieved. The safety profile for liraglutide 3.0 mg was generally consistent with that seen with liraglutide in type 2 diabetes.”
According to Dr. Zammit, “Multiple trials have shown that weight loss is effective in reducing the sleep apnoea episodes in people with sleep apnoea, and should be considered an essential element of the treatment plan for overweight people with this condition.”


  • Nescafé 3 in1 LifeCycle HEROES return from South Asia

    Donations for Nescafé 3in1 LifeCycle Challenge 2019 can be sent via sms: 5061 7370 = €2.33; 5061 8920 = €6.99; 5061 9229 = €11.65; or via a call to 5160 2020 = €10, 5170 2005 = €15; and 5180 2006 = €25. Bank details are Swift code VALLMTMT, IBAN number MT 18 VALL 22013000000014814521017, Bank name Bank of Valletta, Account number 14814521017.

  • Give a Gift this Christmas which gives back

    The story of medicine is the story of civilization, from an ancient craft of primitive magic and religion to the sophisticated field of science and technology of today.



Connect with other Medical Professionals on fb in a closed facebook group


We use cookies to improve our website. By continuing to use this website, you are giving consent to cookies being used. More details…